Therapeutic antibody
development

  • Antigen to bioproduction
  • Hybridoma development
  • Phage display services
  • Antibody humanization
  • Antibody affinity maturation by phage display
  • Bispecific antibody development
  • ADC development

Antibody production

  • Polyclonal antibody production
  • Monoclonal antibody production
  • Hybridoma development
  • Phage display (scFv, VHH, Fab) immune and naïve libraries

Application guaranteed or no fee
Instant online quotation!

Protein production

  • Protein production in 5 expression systems: E. coli, B. subtilis, yeast (P. pastoris& S. cerevisiae), Baculovirus insect cells, mammalian cells.
  • High throughput protein expression
  • Recombinant protein production

Proprietary high performance cell lines

Custom peptide
synthesis

  • Peptide synthesis
  • Peptide conjugation
  • Peptide modification
  • Peptide libraries

Instant online quotation!

Gene
synthesis

  • Custom gene synthesis
  • Gene subcloning
  • Mutagenesis
  • Gene library construction

Starting from 0.18€/bp
Guaranteed service
Fast delivery
Instant online quotation!

Bio
production

  • Transient antibody production
  • Stable cell line antibody production
  • XtenCHOTM, unique productivity

IP free cell lines available
Fermenters & bioreactors

Bio
analytics

  • Antibody affinity measurement (KD)
  • Antibody sequencing
  • Glycosylation profile analysis
  • Endotoxin detection

Integrated solutions

Custom assay
development

  • Custom ELISA Kits
  • ELISA sandwich development
  • Competitive ELISA development

One stop solution from gene
synthesis to kit delivery
Guaranteed service

Testimonial

We collaborated with ProteoGenix for the development of monoclonal antibodies targeting a cell protein. The specificity, functionality and strong affinity of the antibodies developed convinced us to move forward with further humanization and bispecific development.

We appreciated the strong technical and scientific support of our contact which was decisive for the success of our project.

The word of our CEO

As a cofounder of ProteoGenix, I feel extremely proud and privileged to lead a team of spectacularly devoted and talented scientists committed in implementing our strong company values. Our contribution to the fascinating biopharma industry increases the proportion of monoclonal antibodies of any kind of format reaching the market and consequently improves human health.

The engineering of monoclonal antibodies into high potency IgGs, bi-specific antibodies, ScFvs or antibody-drug-conjugates (ADC) or any other format is an exciting task that we perform with passion every day. Our deep involvement in moving all biomolecules forward to the clinic in the best way reflects today’s incredible associated societal expectations. On behalf of ProteoGenix team, I look forward to serving you with sincere pleasure, carrying out your monoclonal antibody productions and pushing your leads to the clinic and eventually to the market.

ProteoGenix, a leading antibody
production company

ProteoGenix is a leading antibody production company founded in 2003. Our integrated solutions from gene to biotherapeutics& diagnostics make us the preferred partner of pharmaceutical & biotech companies for their custom assay development and therapeutic antibody discovery :

Antibody generation including antigen design: hybridoma technology or phage display
Antibody engineering: humanization, affinity maturation, reformatting (bispecific antibodies, ADC…), subtype or isotype switching…
Antibody production: recombinant monoclonal antibody production, stable cell line development…
Protein production: E. coli, B. subtilis, yeast, insect cells, mammalian cells
Custom peptide synthesis
Custom gene synthesis

Let’s partner and push your biotherapeutics to the clinic!

2

Therapeutic antibodies on the market

25

Average years of experience of our experts

30+

Antibodies in preclinical clinical phases

2003

ProteoGenix inception

Integrated solutions for therapeutic
antibody development

Scientific corner

Social media

Meet ProteoGenix

Forum de la recherche en Cancérologie - Research2Business Oncology meeting April 4-5, Villeurbanne, France

12th Annual Proteins & Antibodies Congress, 6th Annual Peptides Congress and 6th Annual Biosimilars & Biobetters Congress April 24-25, London, England

Meet2Win May 21-22, Bordeaux, France

Innovation and New Trends in Biopharma Outsourcing June 18-19, Paris, France

ProteoGenix had an inestimable impact on
our therapeutic antibody development

Adam, Senior Scientist in Cambridge

They trust us